Breast

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024

Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.

Key Points: 
  • Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
  • The results we will present at the AACR Annual Meeting will highlight the preclinical differentiation of our two lead candidates, TUB-030 and TUB-040.
  • The full abstracts will be published on March 22, 2024, in an online-only proceedings supplement to the AACR journal, Cancer Research.
  • The company will issue a press release detailing the full preclinical data following the presentation at AACR.

Team SAMBAI, Yemaachi Biotech, Named as Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024

Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.

Key Points: 
  • Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.
  • “We are confident that this work will be fruitful and will contribute to innovations that will benefit patients globally.
  • We are honored by Team SAMBAI’s belief in our scientific work and impact-driven mission.”
    Inequities in cancer prevention, screening, diagnosis, treatment, and research lead to disparities in cancer incidence and mortality and are a major public health concern.
  • Cancer Grand Challenges is a global funding initiative, co-founded by Cancer Research UK and the National Cancer Institute in the US, that supports a community of diverse, global teams to come together, think differently and take on cancer’s toughest challenges.

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

Retrieved on: 
Monday, March 4, 2024

The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer.

Key Points: 
  • The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer.
  • One MAA is for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment.
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.
  • “The EMA validation is an important first step toward bringing this TROP2 directed antibody drug conjugate to eligible patients in Europe with nonsquamous lung cancer and HR positive, HER2 negative breast cancer,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

Retrieved on: 
Wednesday, February 28, 2024

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.

Key Points: 
  • Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.
  • Offering more effective personalized screening solutions supports Exact Sciences’ commitment to help detect cancer earlier.”
    For patients already diagnosed with cancer, knowing about certain gene variants can help create individualized treatment plans for patients.
  • Exact Sciences’ customer care teams are available to help patients explore the testing process and understand possible results and outcomes.
  • The test is processed in Marshfield, WI at PreventionGenetics, an Exact Sciences laboratory qualified to perform high-complexity clinical laboratory testing that has been providing quality genetic testing since 2004 and joined Exact Sciences in 2022.

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Retrieved on: 
Monday, February 26, 2024

“These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors.

Key Points: 
  • “These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors.
  • JANX007 is in a Phase 1a clinical trial in subjects with advanced or metastatic prostate cancer (mCRPC).
  • As of February 12, 2024, 23 subjects were treated with JANX007 in the dose escalation portion of the Phase 1a clinical trial.
  • Based on this safety profile, we are continuing in the dose escalation and optimization portion of the trial for JANX008.

CAP Updates Validation of Immunohistochemical Assays Testing Guideline for Precise Results, Improved Patient Care

Retrieved on: 
Friday, February 23, 2024

The College of American Pathologists (CAP) updated the “Principles of Analytic Validation of Immunohistochemical Assays” guideline to provide increased precision and accuracy of clinical immunohistochemical assays.

Key Points: 
  • The College of American Pathologists (CAP) updated the “Principles of Analytic Validation of Immunohistochemical Assays” guideline to provide increased precision and accuracy of clinical immunohistochemical assays.
  • This update assesses evidence published since the release of the original guideline in 2014 and provides new recommendations on how to analytically validate/verify immunohistochemical assays used for diagnostic and predictive purposes.
  • “This updated guideline provides new and revised recommendations for analytic validation/verification of immunohistochemical assays, which often guide therapeutic decision making for cancer treatment,” explains guideline chair, Jeffrey D. Goldsmith, MD, FCAP.
  • Current tools, resources, and information for the Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update can be found on the guideline webpage on cap.org.

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

Retrieved on: 
Thursday, February 22, 2024

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancers, today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancers, today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.
  • The compassionate use study results highlight clinical effects studied in 46 patients with advanced metastatic cancers of different origin (prostate, breast, ovarian, pancreatic, colorectal, stomach, non-small cell lung, bowel, and melanoma) after treatment with a rectal formulation of pancreatic proenzymes.
  • Nineteen of 46 patients (41.3%) with advanced malignant diseases, most of them suffering from metastases, had a survival time significantly longer than the expected life span (mean survival of 9.0 months vs life expectancy of 5.6 months), with no severe or serious adverse events related to administration.

China Oncology Drugs Market Research Report 2024-2028 Featuring Major Players - Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche, Johnson & Johnson, AbbVie, AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 20, 2024

High treatment expenses, inadequate insurance, and lack of know-how may also prevent sufferers' capacity to get hold of better oncology treatments in China.

Key Points: 
  • High treatment expenses, inadequate insurance, and lack of know-how may also prevent sufferers' capacity to get hold of better oncology treatments in China.
  • 2.3 Million Oncology deaths are pronounced in China, making Oncology liable for approximately 1 of 5th of all-purpose deaths within the China.
  • NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) and other rising remedies are poised to dominate ChinaOncology drugs market, securing the highest market proportion.
  • This shift signifies a dynamic panorama in China Oncology drugs market, reflecting a growing attention on revolutionary procedures and a broader commitment to preventing oncology comprehensively.

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

Retrieved on: 
Tuesday, February 20, 2024

Specifically, the company will provide clinical efficacy and safety updates to report on progress towards identifying doses for expansion studies with JANX007, and on early dose escalation data for JANX008.

Key Points: 
  • Specifically, the company will provide clinical efficacy and safety updates to report on progress towards identifying doses for expansion studies with JANX007, and on early dose escalation data for JANX008.
  • The company anticipates providing an update on identifying doses to be evaluated in expansion cohorts for JANX007 in 2H 2024.
  • Janux’s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with mCRPC.
  • In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.

New Data Shows That Engaging Patients with Relevant Cancer-Prevention Information During Check-In Increases Screening Rates

Retrieved on: 
Tuesday, February 20, 2024

The analysis revealed that when patients were shown relevant and accurate cancer prevention information while checking in for a visit with their doctor, they found the information helpful and said they would discuss preventive screenings with their doctor or request appointments.

Key Points: 
  • The analysis revealed that when patients were shown relevant and accurate cancer prevention information while checking in for a visit with their doctor, they found the information helpful and said they would discuss preventive screenings with their doctor or request appointments.
  • “We underestimate the lifesaving value of clear communications directly to patients about the importance of cancer screenings,” said Hilary Hatch, PhD, a clinical psychologist and Phreesia’s Chief Clinical Officer.
  • One health system asked more than 87,000 patients about mammogram screenings, and 32% of them requested a mammogram appointment.
  • "We believe that engaging patients with high-quality and relevant information about their health results in better health outcomes," said David Linetsky, SVP, Life Sciences, at Phreesia.